Spark Therapeutics vs Transcripta Bio

Spark Therapeutics vs Transcripta Bio, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Spark Therapeutics is on 58/100 and Transcripta Bio on 54/100.

Spark Therapeutics logo
Spark TherapeuticsA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
Try Spark Therapeutics
Transcripta Bio logo
Transcripta BioAI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
Try Transcripta Bio

Where each one leads

Spark Therapeutics

  • our overall score: 58/100 against 54/100
  • domain rating: 80/100 against 37/100
  • funding raised: $82.8M against $24.0M

Transcripta Bio

  • agent readiness: 49/100 against 39/100

At a glance

MeasureSpark TherapeuticsTranscripta Bio
What it isA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
CategoryBiotechnology, Gene Therapy, Healthcare, PharmaceuticalsBiotechnology, Artificial Intelligence, Drug Discovery, Neurology
Sells toBusiness modelB2BB2B
OfferingServicesPlatform
Founded20132023
HeadquartersPhiladelphia, United StatesPalo Alto, United States
StatusActiveActive

Size, funding and growth

MeasureSpark TherapeuticsTranscripta Bio
Total funding$82.8M$24.0M
Latest roundSeries BSeries A

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureSpark TherapeuticsTranscripta Bio
StartupHub scoreOur 0-100 rating58/10054/100
Traction40/10037/100
Team90/10050/100
Search visibility13/10017/100
Quality65/10068/100
Agent readinessHow well an AI agent can read and act on the siteF (39/100)D (49/100)
Domain ratingLink authority, 0-10080/10037/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureSpark TherapeuticsTranscripta Bio
CDNCloudflareNot detected
FrameworksJqueryNext.js, Tailwind CSS
AnalyticsGoogle Tag ManagerGoogle Analytics 4

What users say

MeasureSpark TherapeuticsTranscripta Bio
Reddit sentimentThreads we track1 positive, 0 negative across 3 threads1 positive, 0 negative across 1 thread
Spark Therapeutics
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings.
r/conspiracy
Transcripta Bio
Transcripta Bio Wins the Genomics Category 🧬💻. Transcripta Bio took home the trophy for Genomics, and for good reason. They are bridging the gap between massive transcriptomic data and actual drug candidates.
r/AIDiscoveryAward

Spark Therapeutics vs Transcripta Bio: common questions

Which is better, Spark Therapeutics or Transcripta Bio?

On our 0-100 score Spark Therapeutics rates higher (58/100 against 54/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.

How do Spark Therapeutics and Transcripta Bio compare on the numbers?

Spark Therapeutics leads on our overall score (58/100 against 54/100), domain rating (80/100 against 37/100), funding raised ($82.8M against $24.0M). Transcripta Bio leads on agent readiness (49/100 against 39/100).

What do real users say about Spark Therapeutics and Transcripta Bio?

Spark Therapeutics: 1 positive and 0 negative mentions across 3 Reddit threads we track, mostly in r/conspiracy. Transcripta Bio: 1 positive and 0 negative mentions across 1 Reddit threads we track, mostly in r/AIDiscoveryAward.

Read the full Spark Therapeutics review and pricing or the Transcripta Bio review and pricing. You can also browse other Spark Therapeutics alternatives we track.